Use-results surveillance of TALYMUS ophthalmic suspension 0.1% (tacrolimus) in severe allergic keratoconjunctivitis.

Use-results surveillance of TALYMUS ophthalmic suspension 0.1% (tacrolimus) in severe allergic keratoconjunctivitis. - Use-results surveillance of TALYMUS ophthalmic suspension 0.1% (tacrolimus) in severe allergic keratoconjunctivitis.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000008640

Enrollment

1000

Registered

2012-08-11

Start date

2008-05-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe allergic keratoconjunctivitis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Severe allergic keratoconjunctivitis patients whom the prior treatment with anti-allergic agents had been ineffective

Exclusion criteria

Exclusion criteria: Subjects are ineligible to participate in this surveillance, if they: 1. Have a known hypersensitivity to tacrolimus hydrate or to any component of this drug 2. Are suffering from infectious eye disease 3. Are pregnant or may possibly be pregnant

Design outcomes

Primary

Measure	Time frame
Mean change in the total score of objective clinical signs	—

Countries

Japan

Outcome results